Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)
| العنوان: | Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1) |
|---|---|
| المؤلفون: | Uli C. Broedl, Hans-Juergen Woerle, Stefan Kaspers, Jens Eilbracht, Thomas R. Pieber, Odd Erik Johansen, Nima Soleymanlou, Jessica Cescutti, S. Famulla |
| المصدر: | Diabetes, Obesity & Metabolism |
| بيانات النشر: | Blackwell Publishing Ltd, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Glycosuria, Adult, Male, medicine.medical_specialty, type 1 diabetes, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Placebo-controlled study, Urology, Pharmacology, Hypoglycemia, Placebo, Endocrinology, Double-Blind Method, Glucosides, Germany, Weight Loss, Internal Medicine, Empagliflozin, pharmacodynamics, Medicine, Humans, Hypoglycemic Agents, Insulin, Benzhydryl Compounds, Glycated Hemoglobin, Type 1 diabetes, Dose-Response Relationship, Drug, business.industry, SGLT2 inhibitor, Original Articles, Middle Aged, medicine.disease, Diabetes Mellitus, Type 1, Treatment Outcome, Pharmacodynamics, Austria, Original Article, Drug Therapy, Combination, Female, medicine.symptom, pharmacology, business |
| الوصف: | Aims To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes. Methods A total of 75 patients with glycated haemoglobin (HbA1c) concentrations of ≥7.5 to ≤10.5% (≥58 to ≤91 mmol/mol) were randomized to receive once-daily empagliflozin 2.5 mg, empagliflozin 10 mg, empagliflozin 25 mg, or placebo as adjunct to insulin for 28 days. Insulin dose was to be kept as stable as possible for 7 days then adjusted, at the investigator's discretion, to achieve optimum glycaemic control. The primary exploratory endpoint was change from baseline in 24-h urinary glucose excretion (UGE) on day 7. Results Empagliflozin significantly increased 24-h UGE versus placebo on days 7 and 28. On day 28, adjusted mean differences with empagliflozin versus placebo in changes from baseline in: HbA1c were −0.35 to −0.49% (−3.8 to −5.4 mmol/mol; all p |
| اللغة: | English |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6f49303d66f4a3248775a58b92f3aacTest http://europepmc.org/articles/PMC4745028Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b6f49303d66f4a3248775a58b92f3aac |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|